ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 117

Family Impact of Juvenile Localized Scleroderma

Katia Milovanova1, Vimal Prajapati 2, Merna Adly 2, Rebeka Stevenson 3, Brendan Lethebe 2 and Nadia Luca 2, 1University of Alberta, Edmonton, Alberta, Canada, 2University of Calgary, Calgary, Alberta, Canada, 3Cochrane, Alberta, Canada

Meeting: 2020 Pediatric Rheumatology Symposium

Keywords: family studies, Morphea, quality of life

  • Tweet
  • Email
  • Print
Session Information

The 2020 Pediatric Rheumatology Symposium, originally scheduled for April 29 – May 2, was postponed due to COVID-19; therefore, abstracts were not presented as scheduled.

Date: Saturday, May 2, 2020

Title: Poster Session 3

Session Type: ACR Abstract Session

Session Time: 4:15PM-5:15PM

Background/Purpose: Juvenile localized scleroderma (jLS) is a rare autoimmune disease that can lead to significant morbidity. Previous studies have focused on predictors of patient health-related quality of life (HRQOL) and self-perception. The purpose of this study is to measure family functioning in patients with jLS and to identify predictors of family impact in this population. We hope these results may help tailor resources for families most at risk of impacted family functioning due to having a child with jLS.

Methods: We included data from patients with jLS (any subtype) followed at a specialized multi-disciplinary (pediatric rheumatology-dermatology) clinic over two years. The primary outcome measure was the PedsQL Family Impact Module (PedsQL-FIM; range is 0-100). This questionnaire was prospectively completed by patients and guardians at each visit, along with the Child Health Assessment Questionnaire (CHAQ), Child Dermatology Life Quality Index (CDLQI), the PedsQL Paediatric Quality of Life Inventory (Generic Core Scales), and the Peds QL Rheumatology Module. Clinical data was provided by the consultant pediatric rheumatologist and dermatologist, including measures of disease activity via the modified Localized Skin Severity Index (mLoSSI) and disease damage via the Localized Scleroderma Damage Index (LoSDI). Fisher’s exact and Wilcoxon Sum Rank tests were used for univariate analysis. Linear mixed model regression analysis was used to evaluate the effect of time and to identify potential predictors of family impact.

Results: Twenty patients with jLS were included in the analysis. The median age was 12.8 years (IQR=11.43-14.80), and 65% were female. The majority (60%) of patients had linear subtype jLS with limb distribution.  At baseline, median mLoSSI score was 1.00 (IQR=0.0 – 3.0) and median LoSDI score was 12.5 (IQR=6.0-18.3). The median baseline PedsQL-FIM score was 80.9 (IQR=76.6-97.4). In univariate analysis, gender did not predict the PedsQL-FIM score. Linear mixed model regression did not show a significant relationship between Family Impact scores and time. Regression models adjusted for time, age and gender showed that higher disease activity as well as methotrexate treatment both had borderline significance for predicting increased Family Impact score (p=.52 and p=.06, respectively). Additional predictors identified include all three PedsQL Generic Core scores (Physical, Psychosocial and Total) (all p< .001); high patient HRQOL was associated with better family functioning. Four of the PedsQL Rheumatology Module dimensions also had strong positive relationships with the Family Impact total score: Pain & Hurt (p< .001), Treatment (p< .001), Worry (p< .001) and Communication (p< .01).

Conclusion: Family functioning in jLS is overall mildly decreased. There is a trend towards worse family functioning with higher disease activity and methotrexate use. In addition, patients who report better HRQOL have better family functioning. Pain, Treatment, Worry and Communication scores of the PedsQL Rheumatology Module predict family functioning. These identified factors can be targeted to better prepare families for daily living with a child who has jLS. 


Disclosure: K. Milovanova, None; V. Prajapati, None; M. Adly, None; R. Stevenson, None; B. Lethebe, None; N. Luca, None.

To cite this abstract in AMA style:

Milovanova K, Prajapati V, Adly M, Stevenson R, Lethebe B, Luca N. Family Impact of Juvenile Localized Scleroderma [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 4). https://acrabstracts.org/abstract/family-impact-of-juvenile-localized-scleroderma/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2020 Pediatric Rheumatology Symposium

ACR Meeting Abstracts - https://acrabstracts.org/abstract/family-impact-of-juvenile-localized-scleroderma/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology